Urelumab - Bristol-Myers Squibb

Drug Profile

Urelumab - Bristol-Myers Squibb

Alternative Names: Anti-4-1BB monoclonal antibody; Anti-CD137 monoclonal antibody - Medarex/Bristol-Myers Squibb; BMS-663513; BMS-66513; ONO-4481

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; National Cancer Institute (USA); Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Chicago
  • Class Antineoplastics; Disulfides; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Glioblastoma; Multiple myeloma
  • No development reported Colorectal cancer; Head and neck cancer; Malignant melanoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Mar 2018 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease) in USA (IV) (NCT03431948)
  • 13 Feb 2018 Bristol-Myers Squibb and University of Chicago plans a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (NCT03431948)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top